Quarterly report · Q2
4548.TEDINET S100SALX
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥79.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥77.8bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥71.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥69.8bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.0bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥490m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥268m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥731m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.54 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.93 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.72 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥420m |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 525
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)三澤 幸之助 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)池田 徹 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 17258000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 18061000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 33456000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 3600000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 2327000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 3069000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 3141000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 2102000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 2236000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 5173000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 5021000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 3921000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 69753000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 71544000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 67216000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 77823000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 79620000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 75625000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 56.32 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 38.54 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 40.49 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.896 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.899 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.889 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 268000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | -490000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1574000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | 1338000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -4578000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | 3365000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -1883000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -731000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -3244000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 24391000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 20987000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 25798000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 29.72 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 3.93 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 56814093 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 56814093 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 56814093 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 56814093 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |